European Journal of Rheumatology
Original Article

Effects of biologic drugs on the prognosis of rheumatoid arthritis among patients with poor diabetes control

1.

Division of Rheumatology, Department of Medicine, Showa University, Tokyo, Japan

2.

Department of Nursing, Showa University, Tokyo, Japan

Eur J Rheumatol 2020; 7: 60-63
DOI: 10.5152/eurjrheum.2019.19144
Read: 289 Downloads: 193 Published: 07 January 2020

Objective: To investigate the effects of biological disease-modifying antirheumatic drugs (bDMARDs) on diabetes control among patients with rheumatoid arthritis (RA).

Methods: A total of 296 patients with RA were included in the study. The following background factors were investigated: age, gender, bDMARD type, methotrexate and prednisolone (PSL) dosages, glycated hemoglobin (HbA1c), C-reactive protein, and matrix metalloproteinase-3. We used the simplified disease activity index (SDAI) to evaluate the RA disease activity. Poor diabetes mellitus (DM) control was defined as a HbA1c of 6.0; accordingly, the patients were divided into good and poor DM control groups. SDAI and PSL dosage were the primary endpoints, respectively, 1 year later.

Results: HbA1c ranged from 6.6±0.68 to 6.5±0.82 and 5.1±0.29 to 5.4±0.34 in the poor and good DM control groups, respectively. Although the intergroup difference was significant (p=0.000), there was no significant intergroup difference during the treatment period (p=0.084). The SDAI ranged from 27.7±15.6 to 7.1±8.0 in the group with a poor DM control (n=83) and from 22.9±14.0 to 6.3±7.6 in the group with a good DM control (n=213).

Conclusion: The bDMARD therapy reduced the RA disease activity regardless of a good or poor DM control.

Cite this article as: Miwa Y, Mitamura Y. Effects of biologic drugs on the prognosis of rheumatoid arthritis among patients with poor diabetes control. Eur J Rheumatol 2020; 7(2): 60-3.

Files
ISSN2147-9720 EISSN 2148-4279